Access cutting-edge acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11 treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Houston location
Preparing your pre-screening questions…
Access acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11 specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11 treatment provided free
Check if you qualify for this acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11 clinical trial in Houston, TX
No-Cost Study Care
Local to Houston
Convenient for TX residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and idarubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a antitumor drug, called calicheamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers calicheamicin to kill them. Colony-stimulating factors, such as filgrastim-sndz, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride may kill more cancer cells.
Sponsor: M.D. Anderson Cancer Center
Yes, this clinical trial (NCT00801489) has an active research site in Houston, TX that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11 treatment options in Houston, TX, this clinical trial (NCT00801489) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11 clinical trials near you to find additional studies recruiting in your area.
See all leukemia clinical trials recruiting in Houston — not just this study.
Browse Leukemia Trials in Houston →